Amgen Forks Over Millions to Settle Marketing Charges

Amgen is entering a corporate integrity agreement (CIA) and will pay about $762 million to the U.S. government, 49 states and the District of Columbia over promotional practices for several of its drugs. Approximately $612 million will resolve its civil liability related to Aranesp (darbepoetin alfa), Epogen (epoetin alfa), Neupogen (Filgrastim), Neulasta (pegfilgrastim), Enbrel (etanercept) and Sensipar (cinacalcet) marketing. About $150 million will resolve its criminal liability relating to its marketing of Aranesp.
Washington Drug Letter